A373110 Stock Overview
Engages in the development and production of drugs for cell therapy.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Xcell Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,200.00 |
| 52 Week High | ₩12,900.00 |
| 52 Week Low | ₩4,545.00 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -25.57% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| A373110 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 30.8% | 3.1% | -3.1% |
| 1Y | n/a | 26.7% | -2.4% |
Return vs Industry: Insufficient data to determine how A373110 performed against the KR Biotechs industry.
Return vs Market: Insufficient data to determine how A373110 performed against the KR Market.
Price Volatility
| A373110 volatility | |
|---|---|
| A373110 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A373110's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine A373110's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | n/a | xcell.co.kr/kor/ |
Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. Xcell Therapeutics Inc. was incorporated in 2015 and is based in Seoul, South Korea.
Xcell Therapeutics Inc. Fundamentals Summary
| A373110 fundamental statistics | |
|---|---|
| Market cap | ₩67.69b |
| Earnings (TTM) | -₩9.16b |
| Revenue (TTM) | ₩1.50b |
45.1x
P/S Ratio-7.4x
P/E RatioIs A373110 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A373110 income statement (TTM) | |
|---|---|
| Revenue | ₩1.50b |
| Cost of Revenue | ₩2.97b |
| Gross Profit | -₩1.47b |
| Other Expenses | ₩7.69b |
| Earnings | -₩9.16b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -838.74 |
| Gross Margin | -97.92% |
| Net Profit Margin | -609.73% |
| Debt/Equity Ratio | 3,517.9% |
How did A373110 perform over the long term?
See historical performance and comparison